Trial; drug therapy; mean duration of follow-up	Study population	Mean baseline LDL level	Absolute and relative LDL reduction	Relative reduction in CHD events (%)	Relative reduction in CHD deaths (%)	Relative reduction in total mortality (%)	Relative reduction in revascularization procedure (%)
WOSCOPS3; pravastatin, 40 mg daily; 4.9 years	6,595 men without known CHD	192 mg per dL (4.95 mmol per L)	−50 mg per dL (−1.30 mmol per L); −26%	−31*	−28	−22	−46†
AFCAPS/TexCAPS26; lovastatin, 20 to 40 mg daily; 5.2 years	5,608 men and 997 women without known CHD	150 mg per dL (3.90 mmol per L)	−35 mg per dL (−0.90 mmol per L); −25%	−24*	−27	No reported end point	−33*
4S study4; simvastatin, 20 to 40 mg daily; 5.4 years	4,444 men with CHD	188 mg per dL (4.85 mmol per L)	−66 mg per dL (−1.70 mmol per L); −35%	−34*	−42*	−30*	−37*
CARE study5; pravastatin, 40 mg daily; 5 years	3,583 men and 576 women with CHD	139 mg per dL (3.60 mmol per L)	−42 mg per dL (−1.10 mmol per L); −30%	−24*	−20	−9	−27*
LIPID study9; pravastatin, 40 mg daily; 6.1 years	7,498 men and 1,516 women with CHD	150 mg per dL (3.90 mmol per L)	−35 mg per dL (−0.90 mmol per L); −25%	−23*	−24*	−22*	−20*